These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38769543)

  • 1. IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer.
    Guo J; Wang C; Luo N; Wu Y; Huang W; Zhu J; Shi W; Ding J; Ge Y; Liu C; Lu Z; Bast RC; Ai G; Yang W; Wang R; Li C; Chen R; Liu S; Jin H; Zhao B; Cheng Z
    BMC Med; 2024 May; 22(1):207. PubMed ID: 38769543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eradicating tumor in a recurrent cervical cancer patient with autologous tumor-infiltrating lymphocytes and a modified lymphodepleting regimen.
    Guo J; Luo N; Ai G; Yang W; Zhu J; Li C; Chen R; Zhang C; Liu S; Jin H; Cheng Z
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35177415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors.
    Hirai I; Funakoshi T; Kamijuku H; Fukuda K; Mori M; Sakurai M; Koda Y; Kato J; Mori T; Watanabe N; Noji S; Yaguchi T; Iwata T; Ohta S; Fujita T; Tanosaki R; Handa M; Okamoto S; Amagai M; Kawakami Y
    Cancer Sci; 2021 Aug; 112(8):3163-3172. PubMed ID: 34101300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial.
    Creelan BC; Wang C; Teer JK; Toloza EM; Yao J; Kim S; Landin AM; Mullinax JE; Saller JJ; Saltos AN; Noyes DR; Montoya LB; Curry W; Pilon-Thomas SA; Chiappori AA; Tanvetyanon T; Kaye FJ; Thompson ZJ; Yoder SJ; Fang B; Koomen JM; Sarnaik AA; Chen DT; Conejo-Garcia JR; Haura EB; Antonia SJ
    Nat Med; 2021 Aug; 27(8):1410-1418. PubMed ID: 34385708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
    Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
    Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer.
    Gitto SB; Kim H; Rafail S; Omran DK; Medvedev S; Kinose Y; Rodriguez-Garcia A; Flowers AJ; Xu H; Schwartz LE; Powell DJ; Simpkins F
    Gynecol Oncol; 2020 Jan; 156(1):222-232. PubMed ID: 31818495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
    Amaria R; Knisely A; Vining D; Kopetz S; Overman MJ; Javle M; Antonoff MB; Tzeng CD; Wolff RA; Pant S; Lito K; Rangel K; Fellman B; Yuan Y; Lu KH; Sakellariou-Thompson D; Haymaker CL; Forget MA; Hwu P; Bernatchez C; Jazaeri AA
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.
    Nguyen LT; Saibil SD; Sotov V; Le MX; Khoja L; Ghazarian D; Bonilla L; Majeed H; Hogg D; Joshua AM; Crump M; Franke N; Spreafico A; Hansen A; Al-Habeeb A; Leong W; Easson A; Reedijk M; Goldstein DP; McCready D; Yasufuku K; Waddell T; Cypel M; Pierre A; Zhang B; Boross-Harmer S; Cipollone J; Nelles M; Scheid E; Fyrsta M; Lo CS; Nie J; Yam JY; Yen PH; Gray D; Motta V; Elford AR; DeLuca S; Wang L; Effendi S; Ellenchery R; Hirano N; Ohashi PS; Butler MO
    Cancer Immunol Immunother; 2019 May; 68(5):773-785. PubMed ID: 30747243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma.
    Pillai M; Jiang Y; Lorigan PC; Thistlethwaite FC; Thomas M; Kirillova N; Bridgeman JS; Kueberuwa G; Biswas S; Velazquez P; Chonzi D; Guest RD; Roberts ZJ; Hawkins RE
    Am J Cancer Res; 2022; 12(8):3967-3984. PubMed ID: 36119832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.
    Dudley ME; Gross CA; Somerville RP; Hong Y; Schaub NP; Rosati SF; White DE; Nathan D; Restifo NP; Steinberg SM; Wunderlich JR; Kammula US; Sherry RM; Yang JC; Phan GQ; Hughes MS; Laurencot CM; Rosenberg SA
    J Clin Oncol; 2013 Jun; 31(17):2152-9. PubMed ID: 23650429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8
    Park J; Kwon M; Kim KH; Kim TS; Hong SH; Kim CG; Kang SG; Moon JH; Kim EH; Park SH; Chang JH; Shin EC
    Clin Cancer Res; 2019 Apr; 25(8):2549-2559. PubMed ID: 30659023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
    Chesney J; Lewis KD; Kluger H; Hamid O; Whitman E; Thomas S; Wermke M; Cusnir M; Domingo-Musibay E; Phan GQ; Kirkwood JM; Hassel JC; Orloff M; Larkin J; Weber J; Furness AJS; Khushalani NI; Medina T; Egger ME; Graf Finckenstein F; Jagasia M; Hari P; Sulur G; Shi W; Wu X; Sarnaik A
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis.
    Martín-Lluesma S; Svane IM; Dafni U; Vervita K; Karlis D; Dimopoulou G; Tsourti Z; Rohaan MW; Haanen JBAG; Coukos G
    Ann Oncol; 2024 Oct; 35(10):860-872. PubMed ID: 39053767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors.
    Hall M; Liu H; Malafa M; Centeno B; Hodul PJ; Pimiento J; Pilon-Thomas S; Sarnaik AA
    J Immunother Cancer; 2016; 4():61. PubMed ID: 27777771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence and enrichment of dominant T cell clonotypes in expanded tumor-infiltrating lymphocytes of breast cancer.
    Ham B; Kim SY; Kim YA; Han D; Park T; Cha S; Jung S; Kim JH; Park G; Gong G; Lee HJ; Shin J
    Br J Cancer; 2024 Jul; 131(1):196-204. PubMed ID: 38750113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TOX-expressing terminally exhausted tumor-infiltrating CD8
    Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
    Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Automated Quantitative CD8+ Tumor-Infiltrating Lymphocytes and Tumor Mutation Burden as Independent Biomarkers in Melanoma Patients Receiving Front-Line Anti-PD-1 Immunotherapy.
    Fortman D; Karunamurthy A; Hartman D; Wang H; Seigh L; Abukhiran I; Najjar YG; Pantanowitz L; Zarour HM; Kirkwood JM; Davar D
    Oncologist; 2024 Jul; 29(7):619-628. PubMed ID: 38655867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8
    Park J; Kim JC; Lee YJ; Kim S; Kim SW; Shin EC; Lee JY; Park SH
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 38964784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of auto-tumor infiltrating lymphocytes induced by interleukin (IL)-12 with IL-2 on patients of primary hepatic carcinoma].
    Zhang YX; Wang XY; Liu JB; Zhang SQ; Chen YR
    Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(14):973-6. PubMed ID: 18756970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.